Important aberrations in the SCLC-A subtype comprise amplifications of BCL2, EZH2, and the decrease of CREBBP, whereas SCLC-Y is associated with mutations in the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR signaling pathway.5 This evidence concerns the gene AKT1 and small cell lung carcinoma.